Clinical Laserthermia Systems AB

Equities

CLS B

SE0022049920

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Stockholm Other stock markets 17:00:00 14/06/2024 BST			5-day change	1st Jan Change
6.048 ^SEK	+1.99%		-4.08%	-78.09%

05-31	Clinical Laserthermia Systems to Raise SEK59 Million via Rights Issue	MT
05-29	Clinical Laserthermia Systems AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Clinical Laserthermia Systems AB Appoints Dan J. Mogren as Permanent CEO

May 18, 2022 at 07:30 am

Clinical Laserthermia Systems AB (publ) announced that the Board of Directors has appointed Dan J. Mogren as permanent CEO of CLS. Dan J. Mogren has been acting CEO since December 1, 2020. Before that he was Chief Commercial Officer at CLS 2009-2020.

Latest news about Clinical Laserthermia Systems AB

Clinical Laserthermia Systems to Raise SEK59 Million via Rights Issue	05-31	MT
Clinical Laserthermia Systems AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-29	CI
Clinical Laserthermia Systems AB Enters into an Exclusive Distribution Agreement with MTEC Company	05-14	CI
Clinical Laserthermia Notes US FDA Clearance for ClearPoint's Prism Bone Anchor Accessory	04-30	MT
Clinical Laserthermia Systems AB Presents Initial Data from the Investigator Initiated Trial at Radboud University Medical Center Using the CLS Transberg System	04-11	CI
Clinical Laserthermia Systems Receives Second Order from the National Institutes of Health Clinical Center in the US for its TRANBERG Thermal Therapy System Accessories	04-09	CI
Clinical Laserthermia Systems AB Announces Two Patients with Localized Prostate Cancer Have Been Safely Treated with the Tranberg Thermal Therapy System At the San Luigi Gonzaga University Hospital in Turin, Italy	04-02	CI
Clinical Laserthermia Systems AB's Subsidiary CLS Americas Signs Agreement with ROSE Urology for Treatment of Prostate Cancer Patients with TRANBERG Thermal Therapy System	03-28	CI
Clinical Laserthermia Systems Names Interim CFO	03-22	MT
Clinical Laserthermia Systems AB Announces CFO Changes	03-22	CI
Clinical Laserthermia Systems AB Announces Publication of Preclinical Assessment of A Non-Cooled MR Thermometry-Based Neurosurgical Laser Therapy System	03-11	CI
Clinical Laserthermia Systems AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-23	CI
Clinical Laserthermia Systems AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-23	CI
Clinical Laserthermia Systems Gains Underwriting Commitments for Warrant Series Exercise	02-02	MT
Clinical Laserthermia Systems Files Patent Extension, Expansion for Non-cooled Laser Applicators	01-30	MT
Clinical Laserthermia Systems AB Files A New Patent Application for Expanded and Extended Protection of the Company's Technology for Laser-Based Tissue Ablation Until 2044	01-30	CI
Clinical Laserthermia Systems Prices Warrants; Stock Falls	01-22	MT
Clinical Laserthermia Systems AB Future-Proofs its Core Technology for MRI-Guided Laser Ablation in A New Agreement with Image Guided Therapy SA	01-17	CI
Clinical Laserthermia Systems Obtains Marketing Approval for Tranberg Thermal Therapy Portfolio in Singapore	01-15	MT
Clinical Laserthermia Systems AB Receives Market Approval for Its TRANBERG Portfolio by HSA in Singapore and Initiates the Process of Commercialization in the Region	01-15	CI
Clinical Laserthermia Systems Gets SEK8 Million Order from ClearPoint Neuro; Stocks Rise	01-09	MT
Clinical Laserthermia Systems Receives SEK 8.1 Million Order from Clearpoint Neuro	01-09	CI
Clinical Laserthermia Systems AB Announces Members of the Nomination Committee Appointments	12-28	CI
Clinical Laserthermia Systems AB Announces Executive Changes	12-19	CI
Clinical Laserthermia Reports First Prostate Cancer Patient Treatment Using Tranberg Therapy	12-05	MT

Chart Clinical Laserthermia Systems AB

Duration

Period

More charts

Company Profile

Clinical Laserthermia Systems AB is a Sweden-based company active in the medical equipment industry. The Company develops and markets a product for the treatment of solid cancer tumors. The product is based on Immunostimulating Laser Thermo Therapy (imILT). imILT method can be used for all tumors in solid organ and the potential market is considerable. Examples of tumors which are suitable for treatment are those found in liver, breast, lung, prostate, kidney, pancreas and thyroid. Clinical Laserthermia Systems AB's treatment system consists of two main parts: a mobile laser device and a sterile patient unit for single use. The Company's product is intended for medical professionals within surgical oncology or interventional radiology within oncology. In April 2014, the Company announced the establishment of a subsidiary in the United States.

Sector

Advanced Medical Equipment & Technology

Calendar

22/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Clinical Laserthermia Systems AB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Quarterly revenue - Rate of surprise

Company calendar

Sector Laser Equipment

	1st Jan change	Capi.
CLINICAL LASERTHERMIA SYSTEMS AB	-78.09%	4.51M
EL.EN. S.P.A.	-3.23%	808M
SISRAM MEDICAL LTD	-30.61%	219M
LASEROPTEK CO., LTD.	-31.50%	78.95M
MODULIGHT OYJ	+15.84%	61.92M

Laser Equipment